Mejorar la prevención de la trombosis y las complicaciones cardiovasculares durante la pandemia de COVID-19

Bulut, 2020, Epidemiology of COVID-19, Turk J Med Sci, 50, 563, 10.3906/sag-2004-172 Chan, 2020, COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western Medicine for the management of 2019 novel coronavirus disease, Am J Chinese Med., 48, 737, 10.1142/S0192415X20500378 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.1017 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768 Onder, 2020, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy., JAMA, 323, 1775 Middeldorp, 2020, Incidence of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost, 18, 1995, 10.1111/jth.14888 European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020. Disponible en: https://www.escardio.org/static_file/Escardio/Education-General/Topic%20pages/Covid-19/ESC%20Guidance%20Document/ESC-Guidance-COVID-19-Pandemic.pdf. Consultado 16 Feb 2021. Susen, 2020, Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring, Crit Care., 24, 364, 10.1186/s13054-020-03000-7 Cattaneo, 2020, Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost., 120, 1230 Levi, 2020, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Haematol, 7, e438, 10.1016/S2352-3026(20)30145-9 Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, 191, 145, 10.1016/j.thromres.2020.04.013 Al-Ani, 2020, Thrombosis risk associated with COVID-19 infection. A scoping review, Thromb Res, 192, 152, 10.1016/j.thromres.2020.05.039 Russo, 2020, Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications, J Cardiovasc Pharmacol, 76, 138, 10.1097/FJC.0000000000000854 Khiali, 2020, A Comprehensive review on tocilizumab in COVID-19 acute respiratory distress syndrome, J Clin Pharmacol, 60, 1131, 10.1002/jcph.1693 Zhou, 2020, Evidence for inflammation as a driver of atrial fibrillation, Front Cardiovasc Med., 7, 62, 10.3389/fcvm.2020.00062 Purohit, 2013, Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation, Circulation, 128, 1748, 10.1161/CIRCULATIONAHA.113.003313 Yao, 2018, Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation, Circulation, 138, 2227, 10.1161/CIRCULATIONAHA.118.035202 Hendren, 2020, Description and proposed management of the acute COVID-19 cardiovascular syndrome, Circulation, 141, 1903, 10.1161/CIRCULATIONAHA.120.047349 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Fauvel, 2020, Critical Covid-19 France Investigators. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study, Eur Heart J, 41, 3058, 10.1093/eurheartj/ehaa500 Prieto-Lobato, 2020, A case series of stent thrombosis during the COVID-19 pandemic, JACC Case Rep, 2, 1291, 10.1016/j.jaccas.2020.05.024 Rodriguez-Leor, 2020, Impacto de la pandemia de COVID-19 sobre la actividad asistencial en Cardiología intervencionista en España, REC Interv Cardiol, 2, 82 Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585 Lazzerini, 2020, COVID-19, arrhythmic risk, and inflammation: mind the gap! Circulation, 142, 7 Gopinathannair, 2020, COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies, J Interv Card Electrophysiol, 1-8 Bhatla, 2020, COVID-19 and cardiac arrhythmias, Heart Rhythm, 17, 1439, 10.1016/j.hrthm.2020.06.016 Vila-Córcoles, 2020, Evaluación de la incidencia y perfil de riesgo de COVID-19 según comorbilidad previa en adultos >50 años del ârea de Tarragona, Rev Esp Salud Publica, 94, e202006065 Inciardi, 2020, Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, 41, 1821, 10.1093/eurheartj/ehaa388 Holt, 2020, New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people, Eur Heart J, 41, 3072, 10.1093/eurheartj/ehaa494 Roden, 2020, Considerations for drug interactions on QTc in exploratory COVID-19 treatment, Circulation, 141, e906, 10.1161/CIRCULATIONAHA.120.047521 Vivas, 2020, Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espanola de Cardiología. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19, Rev Esp Cardiol, 73, 749, 10.1016/j.recesp.2020.04.006 Sociedad Española de Cardiología. InterAAPP. Disponible en: https://secardiologia.es/publicaciones/apps/11508-interaapp Consultado 23 Feb 2021. Miesbach, 2020, COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation, Clin Appl Thromb Hemost., 26, 10.1177/1076029620938149 Helms, 2020, High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med, 46, 1089, 10.1007/s00134-020-06062-x Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, 18, 1094, 10.1111/jth.14817 Poli, 2020, Managing anticoagulation in the COVID-19 era between lockdown and reopening phases, Intern Emerg Med, 15, 783, 10.1007/s11739-020-02391-3 Testa, 2020, Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients, Intern Emerg Med, 15, 751, 10.1007/s11739-020-02331-1 Testa, 2020, Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience, J Thromb Haemost, 18, 1320, 10.1111/jth.14871 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Bhalla, 2018, Meta-analysis comparing the efficacy, safety, and cost-benefit of direct acting oral anticoagulants versus enoxaparin thromboprophylaxis to prevent venous thromboembolism among hospitalized patients, Am J Cardiol, 122, 1236, 10.1016/j.amjcard.2018.06.035 Bhalla, 2020, Contemporary meta-analysis of extended direct-acting oral anticoagulant thromboprophylaxis to prevent venous thromboembolism, Am J Med, 133, 1074, 10.1016/j.amjmed.2020.01.037 Spyropoulos, 2018, MARINER Investigators. rivaroxabán for thromboprophylaxis after hospitalization for medical illness, N Engl J Med, 379, 1118, 10.1056/NEJMoa1805090 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Bansilal, 2015, Am Heart J, 170, 675, 10.1016/j.ahj.2015.07.006 Patti, 2017, Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials, Diabetes Metab Res Rev, 33, 10.1002/dmrr.2876 Plitt, 2020, Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial, Int J Cardiol, 304, 185, 10.1016/j.ijcard.2020.01.009 Escobar, 2019, Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis, Rev Esp Cardiol, 72, 305, 10.1016/j.recesp.2018.02.023 Suárez Fernández, 2018, Seguimiento de las recomendaciones del Informe de Posicionamiento Terapéutico sobre el tratamiento con anticoagulantes orales en pacientes ancianos con fibrilación auricular, Estudio ESPARTA. Med Clin (Barc), 151, 8, 10.1016/j.medcli.2017.07.025 Steinberg, 2018, Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II), J Am Heart Assoc, 7, 10.1161/JAHA.117.007633 Prins, 2013, EINSTEIN Investigators. Oral rivaroxabán versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thromb J., 11, 21, 10.1186/1477-9560-11-21 Ageno, 2016, Safety and effectiveness of oral rivaroxabán versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study, Lancet Haematol, 3, e12, 10.1016/S2352-3026(15)00257-4 Konstantinides, 2020, 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS), Eur Heart J, 41, 543, 10.1093/eurheartj/ehz405 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Eikelboom, 2017, COMPASS Investigators. rivaroxabán with or without aspirin in stable cardiovascular disease, N Engl J Med, 377, 1319, 10.1056/NEJMoa1709118 Frangogianis, 2015, Pathophysiology of myocardial infarction, Comp Physiol, 5, 1841, 10.1002/cphy.c150006 Vogel, 2019, ST-segment elevation myocardial infarction, Nat Rev Dis Primers., 5, 39, 10.1038/s41572-019-0090-3 Coppens, 2019, Synergy of dual pathway inhibition in chronic cardiovascular disease, Circ Res, 124, 416, 10.1161/CIRCRESAHA.118.313141 Ramacciotti, 2019, Rivaroxaban plus aspirin for cardiovascular protection: rationale for the vascular dose and dual pathway inhibition, Thromb Res, 184, 44, 10.1016/j.thromres.2019.09.033 Kupó, 2020, Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis, Angiology, 71, 27, 10.1177/0003319719874255 Chatterjee, 2013, Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials, Coron Artery Dis, 24, 628, 10.1097/MCA.0000000000000031 Marín Ortuño, 2019, Seguridad y eficacia de rivaroxabán en pacientes con fibrilación auricular: una comparación de los estudios EMIR y XANTUS, Rev Esp Cardiol, 72, A6003 European Medicines Agency (EMA). Xarelto, Summary of product characteristics. 2020. Disponible en: https://www.ema.europa.eu/en/documents/product-information/xareltoepar-product-information_en.pdf. Consultado 16 Feb 2021. Liverpool Drug Interactions Group, University of Liverpool. COVID-19 Drug Interactions. 2020. Disponible en: www.covid19-druginteractions.org. Consultado 16 Feb 2021.